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Glucocorticoids (GCs), important regulators of epidermal growth, differentiation, and homeostasis, are used
extensively in the treatment of skin diseases. Using keratin gene expression as a paradigm of epidermal
physiology and pathology, we have developed a model system to study the molecular mechanism of GCs action
in skin. Here we describe a novel mechanism of suppression of transcription by the glucocorticoid receptor
(GR) that represents an example of customizing a device for transcriptional regulation to target a specific
group of genes within the target tissue, in our case, epidermis. We have shown that GCs repress the expression
of the basal-cell-specific keratins K5 and K14 and disease-associated keratins K6, K16, and K17 but not the
differentiation-specific keratins K3 and K10 or the simple epithelium-specific keratins K8, K18, and K19. We
have identified the negative recognition elements (nGREs) in all five regulated keratin gene promoters.
Detailed footprinting revealed that the function of nGREs is to instruct the GR to bind as four monomers.
Furthermore, using cotransfection and antisense technology we have found that, unlike SRC-1 and GRIP-1,
which are not involved in the GR complex that suppresses keratin genes, histone acetyltransferase and CBP
are. In addition, we have found that GR, independently from GREs, blocks the induction of keratin gene ex-
pression by AP1. We conclude that GR suppresses keratin gene expression through two independent mecha-
nisms: directly, through interactions of keratin nGREs with four GR monomers, as well as indirectly, by
blocking the AP1 induction of keratin gene expression.
Glucocorticoids (GCs) mediate their effect through nuclear
receptors, transcription factors that, depending on the pres-
ence or absence of the ligand, regulate gene expression. The
glucocorticoid receptor (GR) is stored in the cytoplasm in its
inactive form, bound to the heat shock protein Hsp90 (49).
Ligand binding causes activation of the receptor, release from
Hsp90, and its translocation to the nucleus. Activated GR
binds specific DNA sequences in target genes, designated glu-
cocorticoid response elements (GREs), and either induces or
suppresses gene transcription (1, 2, 6, 57).
Recent studies have identified a group of proteins that in-
teract with nuclear receptors called coregulators. Depending
on their effect on transcription, the coregulators are designated
as coactivators or corepressors (24, 56). The liganded receptor
binds to the response elements and recruits coactivators (such
as SRC-1, GRIP-1, NCoA, or TIF-2) that interact with cointe-
grators such as p-CIP and CBP/p300 (7, 15, 22, 28, 45, 67). The
cointegrators bind histone acetyltransferase (HAT), which
leads to the induction of transcription (39, 47, 73). In addition,
CBP/p300 itself is a histone acetylase that can induce transcrip-
tion without further interaction with HAT (42, 67). Although
the role of the coregulators in transcriptional regulation by
NRs, including GR, is a rapidly developing area of research,
very little is known about the role of coregulators in active
repression, i.e., in the suppression of transcription by liganded
receptors.
Skin is a major target tissue for GC action. Corticosteroids,
analogs of the glucocorticoid hormone, are the most commonly
used therapeutic agents in dermatology (5, 58, 70). They have
been used as immunosuppressive agents for T-cell or cytokine-
mediated tissue damage. They suppress ICAM-1, interleukin-1
(IL-1), IL-2, IL-6, granulocyte-macrophage colony-stimulating
factor, tumor necrosis factor alpha, and gamma interferon
(IFN-g), which are all components of the immune response (8,
29). In addition, GCs act as growth inhibitory agents and affect
cell-cell interactions (55). However, very little is known about
the molecular mechanisms of GC action in epidermis. There-
fore, to begin to understand such a complex subject, we have
developed a model system in which we use keratins, a family of
differentially expressed epidermal genes, as reporters of GC
action in epidermis. We have focused on the regulation of the
keratin gene expression by GCs because this large family of
epithelium-specific genes has a very precise expression pattern
reflecting the physiological and pathological states of the epi-
thelial cells (4, 17).
Initially, we focused on the following questions: what are the
effects of GCs on epidermal gene expression, how are they
mediated, and most importantly, how do such general and
potent transcription factors specifically target and regulate
gene expression in this tissue? Interestingly, we found that GCs
suppress the expression of a subset of the keratin genes K5-
K14, K6-K16, and K17, whose expression is altered in cuta-
neous diseases (64). GCs regulate these genes through two
different and independent mechanisms. First, GCs directly
suppress transcription through a novel mechanism that in-
volves binding of four monomers of the GR to the keratin
GREs. This mechanism substantially differs from all those pre-
viously described because it uses monomers rather than dimers
of GR, it involves different coregulators, and it uses HAT to
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suppress transcription rather than induce it. The second, inde-
pendent mechanism of GC function is by blocking the AP1-
mediated induction of keratin gene expression. AP1 is com-
monly active in the proliferative and inflammatory processes
for which GCs are usually prescribed.
The effect of GCs on keratin gene expression reflects di-
rectly their specific action in epidermal physiology because
GCs target only the keratin genes expressed during the inflam-
matory response and wound-healing process. The mechanism
through which the regulation occurs is a novel one that repre-
sents an exciting example of tissue specificity in hormone ac-
tion.
MATERIALS AND METHODS
Plasmids, their growth, and their purification. Plasmids pK14CAT, pK5CAT,
pK6CAT, pK16CAT, pK3CAT, pK10CAT, pK17CAT, pK19CAT, pK14M1113,
K17M1, K5M1, and pRSVZ have been described previously (27, 62). The plas-
mids pK8 and pK18 were gifts from R. Oshima (46), pK13 was a gift from J.
Schweizer (61), plasmids containing human GR nuclear receptor and GRE-CAT
were gifts from P. Chambon (18), TK-CAT plasmid was a gift from H. H.
Samuels (14), plasmid containing NCoR was a gift from C. K. Glass (21), plasmid
containing SRC-1 was a gift from B. O’Malley (44), CBP was from R. H.
Goodman (30), and plasmid containing GRIP1 was a gift from M. Stallcup (23).
Plasmids were grown in JM101 E. coli host to saturation density in Luria-Bertani
medium. DNA was extracted and purified using the Mega Prep Kit from Pro-
mega.
Cloning and mutagenesis. We have used a previously described method
(63) to mutagenize the primary GRE site in the K17 promoter and create
K17GREM1. The primers used for the PCRs were K17outF (59-GGGTCTAG
ACAACCCATTTCCCCACCA), K17insR (59-TTTACTAGTTTTTATTCCCC
TGGGCTTTCATCACCA), K17insF (59-TTTACTAGTGAGCAAGCCTGTT
GTAATCGC), and K17outR (59-GGGAAGCTTCATCATGGTGGCGGCGG
C); K17GREM4 was previously described as K17M1 by Radoja et al. (51). K5M1
and K14M1 were also previously described (51, 65).
KRETKCAT contains the acidic signature sequence motif cloned into the
TKCAT (gift from H. H. Samuels). The primers used for the PCR were KREf
(59-TTTTAAGCTTGCCCCCCAGCCACCTG) and KREr (59-TTTTCTCGAC
GCTTTGCTCCTCTGT).
The insert was introduced using HindIII and SalI restriction sites. Positive
clones in all cloning procedures were identified by restriction digestion and
subsequently by sequencing.
Cell growth. HeLa cells were maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% calf serum at 37°C in a 5% CO2 atmosphere
in medium containing penicillin and streptomycin as described earlier (62). The
day before transfection cells were plated onto 60-mm dishes. At 4 h before
transfection the medium was changed to phenol-red-free DMEM supplemented
with charcoal-pretreated 10% calf serum depleted of steroids as described else-
where (62).
Normal human foreskin epidermal keratinocytes were a generous gift from M.
Simon. The cultures were initiated using 3T3 feeder layers as described earlier
(52) and then frozen in liquid N2 until used. Once thawed, the keratinocytes were
grown without feeder cells in defined serum-free keratinocyte medium supple-
mented with epidermal growth factor and bovine pituitary extract (Keratinocyte-
SFM; GIBCO). Cells were expanded through two 1:4 passages before transfec-
tion and transfected at 100% confluency.
Transfection using Ca3(PO4)2. We have generally followed the published
procedure for cells that were at 80% confluence (25). At the time of transfection
3 mg of the CAT plasmid, 1 mg of the nuclear receptor expression vector plasmid,
1 mg of the pRSVZ reference plasmid, and a sufficient amount of carrier were
added into each dish to bring the total to 10 mg of DNA. After transfection cells
were incubated in phenol-red-free DMEM supplemented with charcoal-pre-
treated 10% calf serum depleted of steroids in the presence or absence of 0.1 or
1 mM dexamethasone (DEX; Sigma) in ethanol. Then, 10 nM trichostatin A
(TSA) in ethanol (Wako Bioproducts) was used where indicated. The cells were
harvested at 48 h after transfection by scraping them into 5 ml of phosphate-
buffered saline (PBS), washed once more in PBS, and resuspended in 150 ml of
0.25 M Tris buffer at pH 7.8. All transfections were performed in duplicate
plates, and each transfection experiment was repeated two to five times. The
CAT and b-galactosidase assays were performed as described earlier (25, 62).
Transfection using polybrene with DMSO shock. We used transfections with
polybrene and dimethyl sulfoxide (DMSO) to transfect the DNA into the 100%
confluent keratinocytes as previously described (25). On the day of transfection
cells were washed and incubated in the basal medium without epidermal growth
factor EGF or bovine pituitary extract. Each transfection contained 10 to 15 mg
of keratin-CAT construct and 3 mg of RSVZ construct per dish. The cells were
then incubated with or without 0.1 or 1 mM DEX (Sigma) dissolved in ethanol.
At 36 to 48 h after transfection cells were washed twice with PBS and then
harvested by scraping. The cell disruption by repeated freeze-thaw cycles, as well
as the CAT and b-galactosidase assays, has also been described (25, 62).
Use of antisense oligonucleotides. We used oligonucleotides with the se-
quences CATCTTGCTCGCCTCCCCCGC for human HDAC1 mRNA, ATTT
CCGAGCTACGATCACCCGC for human HAT 1 (HAT1) mRNA (69) and, as
a control, TGGATCATCTTCTGCCATTCT for NF-kB mRNAs. They were
synthesized as phosphorothioates to prolong their half-lives in the cells. These
sequences were designed to bind the initiation codon and the sequences imme-
diately upstream, sites that commonly confer the most efficient antisense block-
ing. The cells were incubated in 1% delipidized medium from the beginning of
transfection. The antisense DNAs were added to the transfected DNA mixture
and subsequently to the medium of the cells transfected with the GR-responsive
construct GRE-TK-CAT and K14CAT. Including the antisense DNA in the
transfection mix has the advantage of ensuring that the cells that received the
transfected DNA also received the antisense oligonucleotides. We added 5 mM
concentrations of the oligonucleotides to the medium immediately after trans-
fection and again 18 h later. Cells were harvested 36 h after transfection, and
enzyme assays were performed.
Enzyme assays. Briefly, the substrate solution contained 6 mg of o-nitrophe-
nyl-D-galactoside (Sigma) freshly dissolved in PM buffer (66 mM Na2HPO4, 33
mM NaH2PO4, 40 mM mercaptoethanol, 2 mM MgSO4, and 0.1 mM MnCl2).
The reaction mixture contained 100 ml of substrate solution, 300 ml of PM2
buffer, and 50 ml of keratinocyte cell extract or 20 to 30 ml of HeLa cell extract.
It was incubated at 37°C until development of the yellow color was obvious,
usually for 0.5 to 1 h. The time of the reaction was recorded, and the reaction was
stopped by the addition of 0.4 ml of 1 M Na2CO3. The optical density at 420 nm
was measured on a spectrophotometer (Gilford).
The CAT reaction mixture contained 69 ml of 1 M Tris HCl (pH 7.8), 1 ml of
14C-labeled chloramphenicol (Cm; 40 to 50 mCi/mmol; New England Nuclear),
20 ml of 4 mM acetyl-coenzyme A solution, 30 to 60 ml of cell extract, and enough
water to bring the total reaction volume to 150 ml. After incubation at 37°C for
1 h, the mixture was extracted into 1 ml of ethyl acetate, phases were separated
by brief centrifugation, the organic layer was transferred to a new tube, and the
solvent was evaporated. The residue was dissolved in 30 ml of ethyl acetate and
separated by thin-layer chromatography on silica gel in chloroform-methanol at
95:5. The plates were exposed to X-ray film for 12 to 24 h, and the intensity of
the radioactive spots was determined using Ambis Radioanalytic System (Ambis,
Inc., San Diego, Calif.). The conversion of chloramphenicol to its monoacety-
lated derivative was kept below 50% by varying the amount of extract or the
duration of the reaction.
All CAT values were normalized for transfection efficiency by calculating the
ratio of CAT activity to b-galactosidase in each transfected plate. Each trans-
fection experiment was separately performed three or more times, with each
datum point resulting from duplicate or triplicate transfections.
Northern blots. Primary human keratinocytes were incubated in the presence
or absence of 1 mM DEX for 6, 12, and 24 h. Cells were harvested by trypsiniza-
tion, and the Quiagen RNeasy Kit was used to isolate total RNA according to the
manufacturer’s protocol. Then, 10 mg of total RNA was loaded per lane on the
agarose gel. Capillary transfer to the Nylon membrane (Amersham) was per-
formed according to a commercial protocol (Amersham). Probes K14cDNA and
HPRTcDNA were labeled using a Random Primer Labeling Kit (Boehringer
Mannheim). Next, 2 3 106 cpm of hybridization solution (Amersham) per ml was
used to hybridize the membrane according to a commercial protocol (Amer-
sham). The membrane was exposed to Kodak X-ray film for 18 h at 270°C.
Electrophoretic mobility shift assays (EMSAs). Escherichia coli-expressed
DNA-binding domain portions of hGR and cT3R were a gift from H. H. Samuels
and have been described previously (16, 66). Oligonucleotides were synthesized
on a Pharmacia Gene Assembler Plus Synthesizer. The sequence of oligonucle-
otides contained a 59-GGG overhang designed for labeling. All double-stranded
oligonucleotides used were gel purified before use. The oligonucleotides used in





A), K17S1 (59-GGGGAAAC), K17S4 (59-GGGTGGTGA), and GRE1/2 (59-G
GGAGAACA).
Double-stranded oligonucleotides corresponding to the sequences above were
labeled with [a-32P]dCTP, using the Klenow fragment of E. coli DNA polymer-
ase I. A total of 30,000 cpm of the resulting probe was mixed with 0.35 pg of
purified receptor proteins and incubated first for 30 min at room temperature
and then for 10 min at 4°C. In the experiments with the dose curve of GR-DBD
10, 15, 20, and 30 pg of purified protein was used. Experiments with full-size
human GR were done similarly using recombinant GR from Affinity Bioreagents
and following their commercial protocol. We used a monoclonal antibody raised
against the DBD region of GR (Affinity Bioreagents). The incubation was done
in a 30-ml volume in 25 mM Tris (pH 7.8), 500 mM EDTA, 88 mM KCl, 10 mM
2-b-mercaptoethanol, 0.1 mg of aprotinin, 0.1 mg of poly(dI-dC), 0.05% (vol/vol)
Triton X-100, and 10% (vol/vol) glycerol. Samples were loaded on a 4% poly-
acrylamide gel and separated by electrophoresis (20 to 25 mA) at 4°C for 2 h with
a buffer containing 10 mM Tris, 7.5 mM acetic acid, and 40 mM EDTA (pH 7.8).
Gels were dried and exposed to X-ray film for 4 h at 270°C. The quantification












of the affinity of protein binding to K17S1 and K17S4 was performed by spot
densitometry using the Alpha Imager 2000 Analysis System from Alpha Innotech
Corporation.
DNase I footprinting. We have followed the general protocol described by
Lakin (31). First, 1 mg of primer K17ft (59-GCCCCCAGCCACCTGGGAGCT)
was labeled by using polynucleotide kinase (Promega) and [g-32P]dATP (Am-
ersham). Next, 1.5 3 106 cpm of each primer was used in the primer extension
reaction with K17ft (59-GCTTGCTCCTCTGTTTCCATTCCCCTGGGCTT
TCATCACCACTGGCCACCTGCCAGCTCCCAGGTGGCTGGGGGC) as
a template and Klenow endonuclease (Boehringer Mannheim). The product was
purified from a 2.5% agarose gel. The band corresponding to the size of the
probe was cut out of the gel and eluted overnight in Tris-EDTA buffer (pH 8) at
4°C; this was followed by ethanol precipitation. Subsequently, two different
reactions were performed in parallel: A/G Maxam-Gilbert sequencing (following
the standard protocol) (35, 36) and DNase I footprinting. For the footprinting
reaction our protocol for gel shifts was used to allow binding of the protein to the
DNA: 25 ml of the binding mix (see gel shift protocol above) was combined with
50 ng of purified receptor protein and 50,000 cpm of probe. After 20 min of
incubation at 4°C, 50 ml of solution containing 10 mM MgCl2 and 5 mM CaCl2
was added and incubated 1 min on ice. Next, 3 ml of the 1:25 dilution of the
DNase I (5 U/ml of stock), a dilution which we have found to be optimal for our
conditions, was added and incubated exactly 1 min on ice. The reaction was
stopped by adding 90 ml of stop solution containing 20 mM EDTA (pH 8.0), 1%
sodium dodecyl sulfate, 0.2 M NaCl, and 100 mg of yeast RNA per ml. DNA was
purified by phenol extraction followed by ethanol precipitation. The pellet was
resuspended in 1.4 ml of 9 M urea, 1% NP-40, and, after mixing, 4.6 ml of
formamide loading buffer (USB) was added. All samples were heated at 90°C for
5 min, chilled on ice, and loaded on the 12% sequencing polyacrylamide gel as
were the samples with the A/G Maxam-Gilbert sequencing reactions of the same
DNA. Gels were subjected to 1,000 V of current for 1 h, dried on the gel dryer,
and exposed to the X-ray film. The footprint localization was determined by the
bands that were protected by the bound protein from cleavage by DNase I, which
appeared on the film as “disappeared” bands when the footprinted sample lane
on the gel was compared with the sample that had no protein in the mix. The
protected bands were then compared with the A/G sequence lane on the same
gel, revealing the nucleotides involved in binding of protein.
Immunohistology. The forearms of healthy volunteers were treated with
0.05% clobetasole propionate (Temovate) twice a day. After 1, 2, 3, or 4 days,
4-mm punch biopsies were taken from the treated site and from an untreated
adjacent site. Biopsies were embedded in Tissue Tek OCT compound (Miles
Scientific), frozen in liquid nitrogen, and stored at 270°C. Frozen sections of 4
to 6 mm were cut (Fung Frigocut 2,800 E Cryostat) and then collected onto
gelatin-coated slides. The sections were stained according to a standard immu-
nofluorescent staining protocol (40). The primary antibody used was polyclonal
rabbit anti-human GR antibody (Affinity Bioreagents). The secondary antibody
used was anti-rabbit fluorescein isothiocyanate preabsorbed with human serum
proteins (Sigma Immunochemicals). An Olympus Microscope was used to ana-
lyze the slides.
RESULTS
Physiology of the GRs in human keratinocytes. We have
found that activation and nuclear translocation of GRs occur
in keratinocytes, both in vivo and in vitro, in the presence of a
specific ligand (Fig. 1 and data not shown). We applied clobe-
tasole propionate, a potent synthetic steroid commonly used in
dermatological therapy, topically to the skin of a volunteer. We
obtained biopsies of treated and untreated skin and stained
tissue sections with GR-specific antibody. GR, found in the
cytoplasm of untreated skin (Fig. 1A), was activated and trans-
located to the nuclei in the treated skin (Fig. 1B). The activa-
tion of GR and its nuclear translocation was detected in all cell
layers of the epidermis. This is a clear demonstration of acti-
vation of a transcription factor in skin caused by a topical
treatment. We have found similar results in vitro using primary
human keratinocytes and HeLa cells (data not shown). Within
6 h of treatment, the GR was translocated to the nuclei of the
both cell types, and the GR remained nuclear during the 24-h
treatment, thus demonstrating the activation and nuclear
translocation of the GR both in vitro and in vivo.
Effects of GR on transcriptional regulation of keratin genes.
To determine the effect of GCs on gene transcription in epi-
dermis, we have measured K14 and K16 mRNA levels during
treatment of keratinocytes with DEX. Results from the North-
ern blot analysis are shown in Fig. 2. Interestingly, the K14
mRNA levels significantly decreased during the 12 h of treat-
ment of keratinocytes by DEX and decrease even further after
24 and 48 h of treatment (Fig. 2). Retinoic acid (RA) also de-
creases K14 mRNA levels, as shown previously (Fig. 2 and
reference 59). In contrast, HPRT mRNA, which was used as a
control, was not significantly changed during the treatments.
Similar results are obtained with K16 mRNA (data not shown).
Taken together, the strong decrease of keratin mRNA levels
by DEX indicates either the inhibition of keratin gene tran-
scription or, alternatively, an increase in keratin mRNA turn-
over.
To determine if DEX inhibits keratin gene expression at the
level of transcription, we tested 10 different keratin gene pro-
moters. We cotransfected keratin gene promoter-CAT con-
structs into keratinocytes and HeLa cells and incubated the
transfected cells in the presence or absence of DEX. We found
FIG. 1. Activation of the GR in human epidermis in vivo. Clobetasole pro-
pionate was applied topically to the skin of a volunteer for 4 days. Biopsies of the
treated and adjacent untreated skin and were sectioned and stained with a
GR-specific antibody. (A) GR is present in the cytoplasm of untreated epider-
mis. (B) Clobetasole propionate caused translocation of the GR from the cyto-
plasm to the nucleus.
FIG. 2. GCs inhibit the transcription of the endogenous K14 keratin gene.
The levels of K14 mRNA were measured by using Northern blot analysis during
keratinocyte treatment with DEX. The K14 mRNA levels significantly decreased
during the 12-h treatment and decreased further during 24- and 48-h treatments.
RA also decreases K14 mRNA levels, as shown previously (59). In contrast,
HPRT mRNA, which was used as a control, was not significantly changed during
the treatments.












that DEX suppressed the expression of the basal layer, as well
as the disease-specific keratins K5, K14, K6, K16, and K17,
three- to fivefold (Fig. 3). In contrast, the expression of the
differentiation-specific keratins, K10 and K3, and the simple
epithelium-specific keratins, K8, K18, and K19, was not affect-
ed by DEX (Fig. 3). The expression of all 10 of these keratins
is regulated by retinoids and thyroid hormones (51, 62, 66).
We used GRE-CAT, the TK promoter that contains a pos-
itive GRE, as a control in our experiments and found it to be
induced 12- to 15-fold by DEX (Fig. 3). We have found similar
results in HeLa cells, i.e., GR suppressed K5, K6, K14, and
K17, whereas it induces GP-CAT (data not shown). In addi-
tion, we have cotransfected a GR-expressing plasmid and
found that the inhibition by DEX was not enhanced by the
addition of exogenous GR, which means that the endogenous
GR is sufficient to regulate fully the keratin gene expression
(data not shown).
Identification of the GREs in keratin genes. We have pre-
viously identified the RA and thyroid hormone response ele-
ments (RARE and TRE) in keratin promoters and found that
they are complex sequences consisting of multiple binding
sites. We hypothesized that if the RAR and T3R bind to the
complex elements, the GR may recognize and bind the same
sites. Therefore, we used these sequences as probes to test the
binding of GR. We have used K17, K5, and K14 nGREs and
recombinant GRs containing the DNA-binding domain (GR-
DBD) in gel shift experiments and found that the sequences
bind GRs in addition to T3R and RAR (Fig. 4). As controls in
binding experiments we used the nGRE identified in the
POMC gene that binds the monomer-plus-dimer of GR (10)
and the consensus GRE spaced by three nucleotides (GRE-3).
Both controls bound the GR as expected, i.e., the POMC
nGRE bound monomer-plus-dimer of GR, whereas the GRE-
3 bound a homodimer of GR.
Are the keratin nGREs true negative elements or does the
promoter context make keratin GREs negative? For example,
the protein-protein interaction between the receptor and an
adjacent protein may cause negative regulation. To test this
possibility, we removed the keratin K17 nGRE from its pro-
moter and cloned it into the TK promoter. The keratin GRE
(KRE) cloned into TK promoter mediated repression by GR
(Fig. 5). This means that KREs are “self-contained negative
REs,” i.e., they contain all of the information necessary to
instruct the receptor to repress, independently of the back-
ground and the context of the promoter. This result is very
important because it proves that KREs are not promoter con-
text dependent.
To map precisely the interactive sites between keratin GRE
and GR, we have used K17GRE in DNase I footprint exper-
iments (Fig. 6). Interestingly, GR-DBD binds initially to a
single monomer binding site at positions 2146 to 2140. As
the protein concentration increases, the GR-DBD footprint
“grows” to occupy a total of four binding sites. In this respect
GR is quite different from T3R. T3R binds to the same region
as GR in the K17 promoter (Fig. 6A). The T3R footprint is
adjacent to the initial GR binding site, and it does not grow
when the protein concentration increases. The footprinting
FIG. 3. GCs suppress transcription of five epidermal keratin genes. Primary human keratinocytes were cotransfected with keratin promoter-CAT constructs, and
the cells were incubated in the absence or presence of DEX. DEX suppresses the expression of the basal-cell-specific keratins K5 and K14 and the disease-associated
keratins K6, K16, and K17. It does not regulate the expression of the differentiation-specific keratins K3 and K10 or the simple epithelium-specific keratins K8, K18,
and K19. GRE-CAT, a positive control, was induced by DEX as expected. The error bars represent the standard errors of the mean of multiple experiments, each
performed with duplicate transfections.
FIG. 4. GR binds to keratin GREs. EMSAs were performed with purified
GR-DBD and K5, K17, and K14 response elements as DNA probes. The neg-
ative GRE characterized in the POMC gene (N-GRE) and the consensus GRE
spaced by three nucleotides (GRE-3) were used as control DNA probes. As
expected, GR binds to N-GRE in a monomer-plus-dimer formation and to
GRE-3 as a homodimer. GR also binds to all three keratin GREs. GR-DBD X1,
X2, and X3 refer to one, two, or three molecules of GR-DBD bound to DNA,
respectively.












experiments identified nGREs in keratin promoters as follows:
in the K5 promoter at 2213 to 2183, in K6 at 2132 to 298, in
K14 at 279 to 249, in K16 at 2162 to 2127, and in K17 at
2172 to 2142 (Fig. 6B). Importantly, we have found that the
sequences responsible for GR binding in the acidic keratin
promoters have .90% identity, constituting a signature se-
quence. In addition, the GREs in the two basic keratin genes
also have a high degree of similarity. However, the acidic
signature sequence is different from the basic signature se-
quence, although both consist of a cluster of binding sites that
bind four monomers of GR.
The identified nGREs in keratin promoters provide binding
to the GR, but it is not clear that those binding sites function
as nGREs, i.e., cause the suppression of transcription by GR.
Therefore, we mutagenized the sequences of nGREs in the
context of their promoters and used the mutants in cotrans-
fection experiments. Introduced mutations altered only the
sequences of the binding sites, whereas the number of the base
pairs within each binding site remained unchanged (51). We
have found that in all three promoters the introduced muta-
tions, K5M1, K14M1, and K17M1, are sufficient to abolish
regulation by DEX (Fig. 6C). Therefore, the identified nGREs
are responsible for the regulation of keratin gene expression by
GR.
Four monomers of GR bind to keratin nGREs. Intrigued by
the growth of the footprint (Fig. 6), we examined carefully the
interaction between the GR and the nGRE. The results from
the gel shift assay confirmed the footprinting results (Fig. 7).
The binding assay with small amounts of the purified GR-DBD
initially revealed a binding pattern that is consistent with the
interpretation of binding of a GR monomer (Fig. 7B; see also
the Discussion). As the concentration of the receptor in-
creases, the monomer is converted into a two-monomer unit,
which further becomes three and finally four. These experi-
ments suggested that the GR binds the keratin GREs as a
monomer rather than as a homodimer. In addition, as the
receptor concentration increases, the GR binds as multiple
monomers (see details in Discussion). Most importantly, we
have obtained the same binding pattern with the full-size GR
(Fig. 7B). Just like the GR-DBD, the full-size GR also binds
the keratin GRE as four monomers. The binding is specific
because an antibody against the DBD of the GR blocks it. The
fact that keratin GREs bind four monomers of the GR, but not
homodimers, implies a new mechanism of negative regulation
through which GR suppresses keratin gene expression.
What is the role of the four binding sites in keratin nGREs?
To characterize the binding sites within the keratin nGREs, we
have used primary and quaternary binding sites as separate
probes in the gel shift experiments. Our results show that the
primary binding site has an approximately 10-fold-higher af-
finity of binding to the GR than the quaternary site (Fig. 7C).
One can speculate further that the binding of GR to nGRE
is cooperative, i.e., binding of the first monomer to the high-
affinity primary site initiates the binding of the remaining three
monomers to the further sites. To test this we have mu-
tagenized the primary binding site and used the mutagenized
GRE as a probe in the gel shift and footprinting experiments.
We found that the binding of the GR to the primary site was
abolished, but the binding to the remaining sites was intact
(Fig. 7D). Thus, the binding is not cooperative. Finally, we
asked whether all four binding sites are necessary for regula-
tion. Therefore, we have mutagenized the primary and, sepa-
rately, the quaternary binding site in the K17 promoter, creat-
ing two mutant promoters: K17GREM1 and K17GREM4 (for
the position of the mutations, see Fig. 7A). Neither mutant
FIG. 6
FIG. 5. Keratin nGRE does not depend on the promoter context. nGRE
from K17 promoter was cloned into the minimal TK promoter and tested for
regulation by DEX in keratinocytes. The nGRE mediates the suppression of the
TK promoter by DEX. The positive control plasmid GRE-TK, containing con-
sensus GRE, similarly cloned into the TK promoter, was activated by DEX,
whereas the minimal TK promoter lacking a response element was not regulated.












promoter was regulated by the GR in cotransfection experi-
ments (Fig. 7E), which means that all four sites are necessary
for regulation. To test the binding of the GR to the mutants,
we used them as probes in footprinting experiments, which
show that in both mutants the GR binding was altered in the
mutagenized regions (data not shown). The binding to unal-
tered sites was unaffected. Taken together, these results indi-
cate that, although they have different affinities of binding to
FIG. 6. Identification and mapping of keratin GREs. (A) Footprinting analysis. Footprints of GR and T3R on K17RE are shown. Gray rectangles represent the
binding of the T3R. The black rectangle on the left represents the initial GR binding site in the K17GRE; increased amounts of GR cause an enlargement of the initial
footprint marked by a black rectangle on the right. (B) Signature sequences of the keratin GREs. Keratin GREs, mapped by footprinting, have a high degree of
sequence homology specific for acidic or basic keratin genes. The acidic signature sequences (top) and basic signature sequences (bottom) are shown, with differences
underlined and triangles marking the insertions. The positions of the sequences in the promoter are indicated. Respective binding sites are shown on the top marked
with roman numerals. The GRE consensus sequence is shown on the top for comparison. (C) Identification of the GREs in keratin promoters by site-specific
mutagenesis. GREs in K5, K14, and K17 promoters were altered to create K5M1, K14M1, and K17M1, respectively, and tested for regulation by DEX in keratinocytes.
Regulation by DEX in all three mutant promoters was abolished, thus confirming that the GREs identified by EMSA and footprinting mediate the regulation of keratin
gene transcription by GR.
FIG. 7. Four monomers of GR bind to the keratin GREs and mediate their suppression. (A) Summary of the sequence analysis. Introduced mutations used in
cotransfection experiments are shown as K17M1 and K17M4. K17S4 and K17S1 probes for the gel shift experiment are shown below with 59 GGG overhang designed
for labeling. (B) Gel shift experiment with recombinant GR-DBD (left), full-size GR (right), and a K17RE probe is shown. GR-DBD binds initially as a monomer.
As the concentration of the GR-DBD increases, two monomers, then three, and finally four are bound to the GREs. A gel shift experiment with recombinant human
full-size GR and a K17RE probe shows a similar binding pattern. A monoclonal GR-specific antibody raised against the DBD region blocks the binding. (C) The
primary and quaternary binding sites in the K17GRE have different affinities of binding to GR. GR binds with similar affinities to the consensus GRE half-site (GRE1/2)
and the primary binding site in K17GRE (K17S1), whereas the quaternary site (K17S4) binds with a significantly lower affinity in gel shift experiments. (D) Binding
of the GR to four binding sites in keratin GRE is not cooperative. Mutation in the primary binding site K17M1 did not affect the binding of the GR to the remaining
three binding sites in keratin K17GRE in the gel shift experiments. (E) The binding of all four monomers is required for the suppression of keratin gene transcription.
Mutations introduced into the primary (K17M1) or the quaternary (K17M4) binding sites abolished regulation by DEX in cotransfection experiments.












the GR, all four binding sites are necessary for the regulation
to occur.
Role of the coregulators in the regulation of keratin genes by
GR. To determine whether known coregulators play a role in
the suppression of keratin gene expression by GR, we have
used vectors expressing coregulators SRC-1 and GRIP-1 in co-
transfection experiments (Fig. 8). Interestingly, SRC-1 and
GRIP-1 had no effect on DEX-mediated suppression of kera-
tin promoters, whereas they enhanced the activation of GRE-
CAT. This means that the coregulatory proteins that enhance
induction of transcription on a consensus (positive) element
are not involved in the suppression of keratin genes by the
same receptor. Since both SRC-1 and GRIP-1 are known as
coactivators, we have tested NCoR, a corepressor, in cotrans-
fection experiments. We have found that, like SRC-1 and GRIP-
1, NCoR had no effect on the keratin gene regulation by DEX
(Fig. 8). As expected, NCoR did not affect GRE-CAT regula-
tion by DEX either (Fig. 8), whereas it enhanced the repres-
sion of TRE-CAT by unliganded T3R (data not shown). We
are currently searching for specific coregulators that interact
with the GR in the context of keratin promoters.
Role of the histone acetylation in the regulation of keratin
genes by GR. Histone acetylase, but not histone deacetylase,
plays a role in the suppression of keratin gene expression by
GR (Fig. 9). We have used antisense technology to test the role
of histone acetylation in this regulation. Using an antisense
approach one can target and block specific mRNAs, thus in-
hibiting the new synthesis of a particular protein. We add-
ed antisense oligonucleotides blocking HAT (AS-HAT) or
HDAC (AS-HDAC) in cotransfection experiments and tested
their effect on keratin gene regulation by GR. Surprisingly, we
found that AS-HAT blocks the repression of keratin gene
expression by DEX, whereas it blocks the induction of GRE-
CAT (Fig. 9A). AS-HDAC had no effect on either keratin
promoters or GRE-CAT. AS-HDAC efficiently blocked the
suppression of TRE-CAT by unliganded T3R, as expected
(data not shown). To confirm that HDAC does not play a role
in the suppression by DEX, we have used TSA, a specific
inhibitor of HDAC (41, 74). We found that TSA did not affect
the suppression of K14CAT by DEX, while it did block the
suppression of TRE-CAT by unliganded T3R (Fig. 9B). Due
to a toxic effect on the cells, TSA decreased the basic activity
of the reporter constructs. However, the fold regulation did not
change in the presence of DEX, thus confirming that HDAC
does not play a role in regulation of keratin gene expression by
DEX. In addition, we have used a plasmid expressing CBP in
cotransfection experiments to confirm our findings with HAT.
CBP, as a component of a coactivator pathway on positive
response elements, has acetylase activity and binds to the re-
ceptor-coregulator complex that further interacts with HAT.
Therefore, if HAT is a component of the repressor complex in
the regulation of keratin genes by GR (as our data indicate),
CBP should be a component as well. We expected that it would
enhance the suppression by DEX. Indeed, we have found that
CBP does enhance suppression of keratin gene suppression by
DEX three- to fivefold (Fig. 9C). The enhancement is concen-
tration dependent. Conversely, CBP enhances the DEX-medi-
ated activation of the positive control GRE-CAT. Taken to-
gether, this means that histone acetylation is involved in the
repression of keratin gene expression by GR. It appears that
both CBP and HAT are auxiliary proteins specific for the
liganded receptor and not direct inducers of transcription.
Furthermore, our results indicate that although HAT activity is
usually associated with gene activation, it may also participate
in gene repression.
Second mechanism of inhibition of keratin gene expression
by GR. GR has been shown to interfere with AP1 in several
systems (3, 20, 38, 48, 68). We have shown previously that K5,
K6, K16, and K17 keratin genes contain functional AP1 sites
(34, 37, 43). Therefore, we have tested the GR effect on keratin
gene regulation by AP1 protein complex. We cotransfected
HeLa cells with components of AP1, Fos, and Jun expressing
plasmids along with K5 and K17 CAT constructs and incu-
bated the cells in the presence or absence of DEX. We found
that DEX significantly blocks the induction of K5 and K17 by
AP1 (Fig. 10). Furthermore, when we used mutants of K5M1
and K17M1, which are not directly regulated by DEX (see Fig.
6C), we found that both mutant promoters were induced by
AP1 and that this induction can be inhibited by DEX (Fig. 10).
This means that GCs, in addition to the direct mechanism, use
another, indirect mechanism of regulating keratin gene expres-
sion, namely, by inhibiting their induction by AP1.
DISCUSSION
The mechanism of suppression of keratin gene transcription
by GR, described here, is an excellent example of tissue spec-
ificity in gene regulation. There are several levels of specificity
evident in this particular mechanism. The first is the DNA
sequence of the nGRE in keratin genes. Keratin GREs con-
stitute the first group of native negative regulatory elements
identified in a gene family. The signature sequences are only
found in the five keratin genes regulated by GR, RAR, and
T3R and not in the genes regulated only by RAR and T3R.
This suggests that the structure of the response elements in
these five keratin genes is customized to suit the purpose of
binding all three receptors. The second level is the binding of
four monomers of GR, arguably the most surprising result in
this study. The unique property of the keratin nGRE is to allow
binding of four GR monomers, and only if all four are bound
does the regulation by GR occur. The third level relates to the
coregulatory proteins. The simplest explanation for their fail-
FIG. 8. Role of the coregulators in regulation of keratin gene expression by
GR. We have tested coactivators SRC-1 and GRIP-1 and corepressor NCoR in
cotransfection experiments with K14CAT (top) and GRE-CAT (bottom). None
of the coregulators tested affected the suppression of keratin gene expression by
DEX. SRC-1 and GRIP-1, but not the NCoR, enhanced the activation of the
positive control, GRE-CAT, as expected.












ure to affect keratin gene regulation is that the GR is in a
monomeric form. The coregulators tested either do not bind
the monomeric GR or cannot fulfill the function if bound to
the monomer. It is also possible that suppression by the ligand-
ed receptor requires its own set of coregulators that are yet to
be discovered. The final level is the histone acetylation, which
was another surprise. Our results indicate that histone acety-
lase, but not histone deacetylase, plays a role in the suppres-
sion of transcription. Taken together, every step in the path of
the suppression of keratin gene expression by GR is different
than those previously described. We believe that this mecha-
nism is specifically designed for the purpose of targeting ker-
atin genes within the target tissue, i.e., epidermis.
We identified the acidic keratin signature sequence, which
was 93% identical, in the K14, K16, and K17 promoters, and
the basic signature sequence, which was 91% identical, in the
K5 and K6 promoters. The acidic and basic signature se-
quences do not have significant homology. Interestingly, the
FIG. 9. HAT, but not HDAC, is involved in the suppression of keratin gene expression by DEX. (A) We added antisense oligonucleotide-blocking HAT (AS-HAT)
and one blocking HDAC (AS-HDAC) into cotransfection experiments. AS-HAT blocked the repression of keratin gene expression by DEX, whereas it blocked the
induction of GRE-CAT. AS-HDAC had no effect on either the keratin promoters or GRE-CAT. (B) TSA, an HDAC inhibitor, does not affect the suppression of
keratin gene expression by DEX. As expected, TSA blocks the inhibition of the positive control, thyroid response element TRE-CAT, by unliganded T3R. (C) CBP
enhances suppression of keratin gene expression by DEX in a dose-dependent manner, whereas it enhances activation of GRE-CAT. Three different amounts of
CBP-expressing plasmid were used (1, 3, and 9 mg).












GR binds to both signature sequences in identical patterns, i.e.,
as four monomers, which means that, although differentially
expressed, K5, K6, K14, K16, and K17 are regulated by GR
through the same mechanism. Our results also emphasize the
important role that the DNA sequence plays in transcriptional
regulation by nuclear receptors. In this mechanism, the struc-
ture and sequence of the nGRE in keratin promoters positions
the receptor in a specific configuration. We believe that the
character of keratin nGRE is the initial signal for suppression.
Negative regulation, or suppression, by GR and other nu-
clear receptors may occur through several different mecha-
nisms, such as direct binding of the receptor to a negative
GRE, e.g., in the keratin genes and the POMC gene (10);
direct interference with transcriptional machinery, e.g., in the
osteocalcin gene where GRE overlaps with the TATA box
(60); protein-protein interactions with positive regulators, e.g.,
AP1, forming an inactive complex (20, 38, 48); and induction of
expression of an inhibitor of transcription, e.g., IkB, through
which GR functionally inhibits those genes induced by NF-kB
(9, 19). The molecular mechanism of keratin gene suppression
by GR described here is one of the rare examples of active
repression. Direct negative regulation proceeds through bind-
ing of the four GR monomers to the keratin GREs. There are
three lines of evidence leading to this conclusion. The first
arises from the gel shift and footprinting experiments. Judging
by the intensity of the bands and binding patterns it is clear that
binding occurs by the addition of monomers one by one, not by
two dimers or a dimer and a monomer. In addition, when one
site is mutagenized the remaining three sites bind three mono-
mers (see Fig. 7D), thus confirming the independent binding of
monomers. The second line of evidence arises from the mu-
tagenesis experiments of the GR binding sites in the keratin
nGRE. Regulation occurs only if all four binding sites are
intact, although their affinities of binding are different. The
third line of evidence arises from the structure and sequence of
the binding sites. Judging by the crystal structure of the GR-
DBD it is not possible to fit the receptor dimer in any two
combinations of the GR binding sites in keratin nGRE (32,
33). According to the current knowledge, the spacing between
the half sites has to be either three or four nucleotides, in the
inverted palindrome orientation. In addition, the sequence of
the consensus binding site seems to be restrictive, i.e., if it is
changed from AGAACA to AGGACA, it changes the affinity
of binding from a preferentially GR binding site to an ER
binding site (53, 54). None of these rules, however, applies to
the identified keratin binding sites. Instead, their structure,
sequence, and orientation preclude the binding of GR ho-
modimers. Consistently, no homology between nGREs in ker-
atin genes and consensus, positive, GRE can be found. There-
fore, multiple monomer binding of the GR is a novel
mechanism of suppression by glucocorticoids, so far found only
in the epidermal keratin genes.
The role of coregulators in this mechanism, although not
defined, is evidently different than what has been described in
the literature. The known general coactivators that interact
with liganded GR and enhance positive regulation do not af-
fect the function of the same receptor when it suppresses
keratin gene expression. The most probable explanation is that
known coregulators do not functionally interact with GR on
keratin nGREs because they cannot function with monomers
of GR. There is some evidence suggesting that coregulators
may interact with two receptors at the same time through
different regions and that their function depends on the posi-
tion and alosteric conformation of the interactive sites (72).
Several tissue-specific coregulators have been described re-
cently (50, 75), raising the possibility that the coregulators
involved in keratin regulatory mechanism might be epidermis
specific rather than general. We are currently investigating
these possibilities.
Coactivators recognize and bind to liganded receptor on one
side and to CBP/p300 on another. CBP/p300, in addition to
being a histone acetylase itself, can also interact with HAT,
causing histone acetylation and further induction of transcrip-
tion. Liganded GR suppresses keratin gene transcription,
which immediately raises the question regarding the role of
histone acetylation in this regulation. One can expect that the
GR on keratin nGREs interacts somehow with other proteins
that interact with histone deacetylase (HDAC) causing repres-
sion of transcription. Interestingly, and much to our surprise,
the results show exactly the opposite: histone acetylase, rather
than deacetylase, participates in the suppression of keratin
gene transcription. This result is further supported by our
finding that CBP as well enhances the suppression of keratin
gene expression by GR. These findings are in contrast to the
previously established paradigm of HAT as a member of the
transcriptional activator complex (39). Our results suggest that
HAT is a coregulator specific for the liganded receptor and is
not directly responsible for induction of transcription. This
leaves open the question of the function of the acetylation of
histones per se in the regulation of transcription. It has been
shown that CBP/p300 can have a repressive function as well
(71). Understandably, our findings raise more questions that
are subject of further studies. However, it is clear that these
findings point toward multiple functions of histone acetylase in
transcriptional regulation dependent on a particular mecha-
nism rather than as a general phenomenon.
Our laboratory and others have previously shown that RA
FIG. 10. GR blocks the induction of keratin gene expression by AP1. We
have cotransfected HeLa cells with Fos and Jun expression plasmids along with
K5 and K17 CAT constructs. The transfected cells were cultures in the presence
or absence of DEX. DEX significantly blocked the induction of K5 and K17 by
the cotransfected Fos and Jun. Furthermore, K5M1 and K17M1, which are no
longer directly regulated by DEX (see Fig. 6C), were induced by AP1, and this
induction was inhibited by DEX. The inhibition of the AP1 is mediated by a
different mechanism that does not depend on GREs in keratin promoters.












and T3 receptors regulate the expression of keratin genes (62,
66). Our finding is that GCs target for regulation only those
keratin genes that are aberrantly expressed in diseased epider-
mis, specifically the basal-cell-specific K5-K14, the activated
keratinocyte-specific K6-K16, and the “inflammation”-specific
keratin K17. GCs do not affect simple or differentiation-spe-
cific keratin genes. The question one must ask is, what is the
biological relevance of this regulation? Long-term topical
treatment by GCs causes thinning of epidermis (58), which
correlates with the suppression of K5-K14 keratin genes, mark-
ers of the basal keratinocytes. In addition, GCs are known to
inhibit the wound healing process, which is attributed to their
growth-inhibitory effect (70). This correlates with the suppres-
sion of K6-K16 keratin genes, markers of activated keratino-
cytes (27). Finally, GCs are most often used therapeutically for
their anti-inflammatory effects. This correlates with the sup-
pression of expression of the K17 keratin gene, which is
present in epidermis only during IFN-g-related inflammatory
processes (26).
We have found that in addition to this direct regulation, the
GR indirectly regulates expression of keratin genes by blocking
AP1 transcription factor. This indirect regulation may be par-
ticularly important in wound healing, psoriasis, and inflamma-
tory dermatoses, which are associated with activation of the
AP1 proteins (11–13). The direct binding of the GR to GRE in
the keratin promoter is not involved in this mechanism, be-
cause the indirect regulatory pathway is still functional in the
K5 and K17 mutant promoters, in which the direct regulation
does not occur. This means that the direct and the indirect
regulatory pathways are independent of each other and may
function at the same time (Fig. 11). Homodimerization of the
GR is not necessary for the interaction with c-Jun, and it is
tempting to speculate that monomers of GR have a dual func-
tion in keratin gene regulation: they directly inhibit the tran-
scription by binding in multiple copies to keratin REs, and they
bind to c-Jun blocking keratin induction by the AP1 complex.
In addition, the dominant-negative GR used to generate trans-
genic mice, as described by Reichardt et al., was impaired in
homodimerization, i.e., it binds to the DNA only as a monomer
(53, 54). Interestingly, the inhibition of AP1 by the GR in this
mouse was intact, and the animal did not have an aberrant skin
phenotype, suggesting that the two mechanisms of regulation
of keratin gene expression in epidermis of this mouse are
intact.
Having potent and general transcription factors, such as
nuclear receptors, is the nature-designed distinct way of reach-
ing specific targets, thus differentially orchestrating gene ex-
pression in different tissues at the same time. We describe here
a novel mechanism of suppression of transcription by GR that
represents an example of customizing a device for the tran-
scriptional regulation to target a specific group of genes in the
target tissue, the epidermis.
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